---
layout: post
title: New Drug Approvals 2011 - Pt. XVII Fidaxomicin (Dificid TM)
date: '2011-06-01T11:39:00.008+01:00'
author: Patricia
tags:
- 2011 New Drugs
- Natural Product Drugs
modified_time: '2012-01-04T09:27:09.505Z'
thumbnail: http://1.bp.blogspot.com/-_J1ESY2mIUc/TfME9S2SarI/AAAAAAAABMc/mMvJQ4nEag0/s72-c/01-05071115fidaxomicin_bottleSM.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6972028215991000029
blogger_orig_url: http://chembl.blogspot.com/2011/06/new-drug-approvals-2011-pt-xvii.html
---

<div style="text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-_J1ESY2mIUc/TfME9S2SarI/AAAAAAAABMc/mMvJQ4nEag0/s1600/01-05071115fidaxomicin_bottleSM.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-_J1ESY2mIUc/TfME9S2SarI/AAAAAAAABMc/mMvJQ4nEag0/s1600/01-05071115fidaxomicin_bottleSM.jpg" /></a></div>
<div style="text-align: center;">
<br /></div>
<br />
<br />
<br />
<center><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/7,0,0,1,0,0,1,1,0" width="400" /></center><center><br />
</center><br />
<div style="text-align: center;">
</div>
<div style="text-align: center;">
<b>ATC code (partial): A07A</b><br />
<br /></div>
On May 27th 2011, the FDA approved Fidaxomicin (Tradename: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=dificid">Dificid</a>; Research Code: PAR-101, OPT-80, NDA 201699), a macrolide narrow spectrum antibacterial drug indicated for the treatment of <span style="font-style: italic;"><a href="http://en.wikipedia.org/wiki/Clostridium_difficile">Clostridium difficile</a><span class="Apple-style-span" style="font-style: normal;">-associated diarrhea (CDAD)</span></span> in adults. <i>Clostridium difficile</i> (<i>C. difficile</i>) is an anaerobic, spore-forming <a href="http://en.wikipedia.org/wiki/Gram_positive">Gram-positive bacteria</a>, and&nbsp;overgrowth of this species can cause severe diarrhea and other more serious intestinal conditions, such as <a href="http://en.wikipedia.org/wiki/Colitis">colitis</a>.  <br />
<br />
<div>
Fidaxomicin is a fermentation product obtained from the <a href="http://en.wikipedia.org/wiki/Actinomycete">Actinomycete</a> <i><a href="http://en.wikipedia.org/wiki/Dactylosporangium">Dactylosporangium</a> aurantiacum</i>. It exerts its therapeutic effect by inhibiting beta subunit of the bacterial enzyme DNA-directed RNA polymerase (RNAP) (UniProt:<a href="http://www.uniprot.org/uniprot/Q890N5">Q890N5</a>), resulting in the death of <i>C. diffi</i><i>cile</i>. Bacterial <a href="http://en.wikipedia.org/wiki/RNA_polymerase">RNA polymerase</a> is a large (~400 kDa) five subunit protein, and is the target of the already approved antibiotic <a href="http://en.wikipedia.org/wiki/Rifampicin">rifampicin</a>. Other treatments for CDAD already in the market include antibiotics such as <a href="http://en.wikipedia.org/wiki/Metronidazole">Metronidazole</a> (trade name Flagyl; ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL137">CHEMBL137</a>) and <a href="http://en.wikipedia.org/wiki/Vancomycin">Vancomycin</a> (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL262777">CHEMBL262777</a>). Patients generally respond to these antibiotic therapies, however there is a risk of recurrent infection associated with these treatments. Fidaxomicin <a href="https://www.ebi.ac.uk/chembldb/index.php/doc/inspect/CHEMBL1155149">has been shown</a> to be more active <i>in vitro</i> than Vancomycin (<a href="http://en.wikipedia.org/wiki/Minimum_inhibitory_concentration">minimum inhibitory concentration</a>&nbsp;(MIC) of 0.12 µg/mL and 1.0 µg/mL, respectively) against <i>C. difficile</i> and <a href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812">also</a> more selective, having limited activity <i>in vitro</i> and <i>in vivo</i> against components of the normal gut flora.<br />
<br />
There are several known structures of bacterial RNA polymerases in complex with various antibiotics, typical is the structure of the <i>Thermus aquaticus</i> RNA polymerase in complex with sorangicin (PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1ynn/summary">1ynn</a>)<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-sIngn2ABm4c/TeYiN8Yko3I/AAAAAAAABMA/doq5G7dogCI/s1600/full1.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="http://1.bp.blogspot.com/-sIngn2ABm4c/TeYiN8Yko3I/AAAAAAAABMA/doq5G7dogCI/s320/full1.png" width="320" /></a></div>
<br /></div>
<div>
<br /></div>
<div>
</div>
<div>
The recommended dose of Fidaxomicin is one 200 mg tablet twice daily for 10 days (equivalent to a daily dose of 380 umol). At therapeutic doses, Fidaxomicin has a minimal systemic absorption, with plasma concentrations of Fidaxomicin and OP-1118, its main and microbiologically active metabolite, in the ng/mL range. The mean terminal half-life (T1/2) of Fidaxomicin and OP-1118 is 11.7 and 11.2 hours, respectively. Fidaxomicin is primarily transformed by hydrolysis at the isobutyryl ester to form OP-1118. Metabolism of Fidaxomicin and formation of OP-1118 are not dependent on cytochrome P450 (CYP) enzymes. Fidaxomicin is mainly excreted in feces, with 92% of the dose recovered as either Fidaxomicin and OP-1118.</div>
<div>
<br /></div>
<div>
</div>
<div>
<img alt="" border="0" id="BLOGGER_PHOTO_ID_5612903325276686818" src="http://2.bp.blogspot.com/-Vuc4scy4row/TeUJ1f25yeI/AAAAAAAAAl4/eM4ghHTZbf0/s400/Fidaxomicin.png" style="cursor: hand; cursor: pointer; display: block; height: 177px; margin: 0px auto 10px; text-align: center; width: 400px;" /></div>
<div>
</div>
<div>
Fidaxomicin (IUPAC: [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9Z,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl]3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate; SMILES: CC[C@H]1\C=C(/C)\[C@@H](O)C\C=C\C=C(/CO[C@H]2</div>
<div>
O[C@@H](C)[C@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@@H](O)[C@H]2OC)\C(=O)O</div>
<div>
[C@@H](C\C=C(/C)\C=C(/C)\[C@@H]1O[C@@H]4OC(C)(C)[C@@H](OC(=O)C(C)C)</div>
<div>
[C@H](O)[C@@H]4O)[C@H](C)O; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL485861">CHEMBL485861</a>; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=46174142&amp;loc=ec_rcs">46174142</a>) has a molecular weight of 1058 Da, an ALogP of 7.7, seven hydrogen bond donors and 18 acceptors, and thus is not rule of five compliant. A notable feature is the 18-member polyene macrolide ring.</div>
<div>
</div>
<div>
<br />
The full prescribing information can be found&nbsp;<a href="http://www.dificid.com/upload/dificid.pdf">here</a>.<br />
<br />
The license holder for Fidaxomicin is <a href="http://www.optimerpharma.com/">Optimer Pharmaceuticals, Inc.</a> and the product website is <a href="http://www.dificid.com/">www.dificid.com</a>.</div>